Rolapitant Combined with 5-HT3 Receptor Antagonist and Dexamethasone for the Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting: A Systematic Review / 中国药房
China Pharmacy
;
(12): 4242-4247, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-704418
ABSTRACT
OBJECTIVE:
To evaluate the effectiveness and safety of rolapitant combined with 5-HT3 receptor antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting systematically,and to provide evidence-based reference in clinic.METHODS:
Retrieved from CJFD,VIP,Wanfang Database,PubMed,EMBase and Cochrane Library,randomized controlled trials (RCTs) about rolapitant+5-HT3 receptor antagonist+ dexamethasone (trial group) vs.placebo combined with 5-HT3 receptor antagonist+dexamethasone (control group) for the prevention of chemotherapy-induced nausea and vomiting.Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane system evaluator manual 5.1.0.RESULTS:
A total of 3 literatures were included,involving 4 RCTs and 2 583 patients.The results of Meta-analysis were as followscomplete remission rate [acute stageRR=1.10,95% CI (1.02,1.19),P=0.01;delay stageRR=1.18,95% CI (1.11,1.25),P<0.001;overall stageRR=1.19,95 % CI (1.12,1.26),P<0.001] and the proportion of patients with ftmctional indexes of vomiting living > 108 [RR =1.10,95 % CI (1.04,1.16),P < 0.001] in trial group were significantly higher than control group,with statistical significance.There was no statistical significance in the incidence of ADR between 2 groups[RR=1.10,95 % CI (0.82,1.47),P=0.52].CONCLUSIONS:
Rolapitant combined with 5-HT3 receptor antagonist and dexamethasone can effectively prevent and relieve chemotherapy-induced nausea and vomiting,and improve the quality of life with good safety.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
/
Practice guideline
/
Systematic reviews
Language:
Chinese
Journal:
China Pharmacy
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS